Thromboelastography Predicts Thromboembolism in Critically Ill Coagulopathic Patients

Area of Science:

• Critical care medicine
• Hemostasis and thrombosis
• Intensive care unit (ICU) management

Background:

• Critically ill patients with abnormal coagulation tests often face decisions regarding anticoagulant prophylaxis due to perceived bleeding risk.
• The management of anticoagulant prophylaxis in these patients remains a clinical challenge.

Purpose of the Study:

• To evaluate the predictive capability of in vitro clot strength, assessed via thromboelastography, for identifying thromboembolism risk in critically ill patients with coagulopathy.
• To determine if clot strength can guide clinical decisions on anticoagulant therapy and blood product transfusion.

Main Methods:

• A prospective cohort study was conducted in a tertiary ICU.
• 215 critically ill patients with coagulopathy (thrombocytopenia or abnormal INR/aPTT) were enrolled.
• Thromboelastography (TEG) was used to measure in vitro clot strength (maximum amplitude).

Main Results:

• 16% of patients developed thromboembolism, predominantly those with normal or increased clot strength (91%).
• Maximum amplitude on TEG showed good predictive ability for thromboembolism (AUC 0.74).
• Increased clot strength was associated with a lower likelihood of requiring blood product transfusions (12.8% vs 69.2%).

Conclusions:

• In critically ill patients with abnormal coagulation profiles, increased in vitro clot strength on TEG is linked to a higher risk of thromboembolism.
• Conversely, normal or reduced clot strength is associated with a reduced risk of requiring blood product transfusions.
• Thromboelastography-derived clot strength may offer valuable insights for managing critically ill coagulopathic patients.